LNK001 / Link Cell Therapies - LARVOL DELTA

Preclinical Evaluation of LNK001: Stringent AND-Gate Fidelity and Potent Efficacy of a Dual-Antigen CAIX/ENPP3 CAR T Cell Therapy for Clear Cell Renal Cell Carcinoma (KCRS 2026) - "Together, these findings provide a strong preclinical foundation for the upcoming Phase 1 clinical trial of LNK001 in patients with advanced and metastatic ccRCC. Keywords CAR T cell therapy, Logic-gated CAR (AND-gate), Clear cell renal cell carcinoma (ccRCC), CAIX / ENPP3, On-target off-tumor toxicity"

CAR T-Cell Therapy • Preclinical • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hematological Malignancies • Oncology • Solid Tumor • CA9 • GZMB • IFNG • LCP2 • TNFA

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2026 ➔ Jul 2026

Enrollment open • Trial initiation date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-1 • PD-L1

LNK001 is a High-Fidelity AND-Logic-Gated CAR T Cell Therapy that Enables Precision Targeting of Clear Cell Renal Cell Carcinoma (ccRCC): Target Discovery and Validation for the ATHENA Phase 1 Trial (KCRS 2026) - "Collectively, these studies form the basis for clinical development of LNK001 in advanced and metastatic ccRCC in a phase 1 clinical trial. Keywords CAR T cell, Kidney cancer"

CAR T-Cell Therapy • IO biomarker • P1 data • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CA9 • LCP2

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P1 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CA9 • PD-1 • PD-L1